92 related articles for article (PubMed ID: 24263076)
21. Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic.
Takami T
Hypertens Res; 2009 Dec; 32(12):1086-90. PubMed ID: 19779491
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
23. Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients.
Tsirpanlis G; Boufidou F; Manganas S; Chantzis K; Bleta A; Stamatelou K; Psimenou E; Nicolaou C
Blood Purif; 2004; 22(6):518-24. PubMed ID: 15557765
[TBL] [Abstract][Full Text] [Related]
24. Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.
Koh KK; Lim S; Choi H; Lee Y; Han SH; Lee K; Oh PC; Sakuma I; Shin EK; Quon MJ
Diabetes; 2013 Oct; 62(10):3547-52. PubMed ID: 23863812
[TBL] [Abstract][Full Text] [Related]
25. Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial.
Conen D; Everett BM; Glynn RJ; Ridker PM
Heart; 2008 Mar; 94(3):e13. PubMed ID: 17923463
[TBL] [Abstract][Full Text] [Related]
26. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.
David S; Kümpers P; Lukasz A; Kielstein JT; Haller H; Fliser D
J Hypertens; 2009 Aug; 27(8):1641-7. PubMed ID: 19390459
[TBL] [Abstract][Full Text] [Related]
27. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
[TBL] [Abstract][Full Text] [Related]
28. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
29. A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age.
Janić M; Lunder M; Šabovič M
Biomed Res Int; 2015; 2015():235709. PubMed ID: 25821790
[TBL] [Abstract][Full Text] [Related]
30. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
[TBL] [Abstract][Full Text] [Related]
31. Renoprotective effect of combining angiotensin II receptor blockers and statins in diabetic rats.
Gao P; Jia RH; Yang DP; Liu HY; Song EF; Chu GL; Ding GH
Chin Med J (Engl); 2005 Apr; 118(7):598-602. PubMed ID: 15820093
[No Abstract] [Full Text] [Related]
32. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
[TBL] [Abstract][Full Text] [Related]
33. Expression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat "Aging-Related Disorders".
Janić M; Lunder M; Novaković S; Škerl P; Šabovič M
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013989
[TBL] [Abstract][Full Text] [Related]
34. Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study.
Ye Z; Zhang L; Xu L; Shi W; Hu H; Shi X; Zhong W; Hou S; Yan H; Zhang B; Xia Y; Wang W; Feng Z; Wang L; Liang Y
Nephrology (Carlton); 2014 Jan; 19(1):40-6. PubMed ID: 24191893
[TBL] [Abstract][Full Text] [Related]
35. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
[TBL] [Abstract][Full Text] [Related]
36. Cardioprotective effect of angiotensin II type 1 receptor antagonist associated with bradykinin-endothelial nitric oxide synthase and oxidative stress in Dahl salt-sensitive hypertensive rats.
Yoshida K; Kobayashi N; Ohno T; Fukushima H; Matsuoka H
J Hypertens; 2007 Aug; 25(8):1633-42. PubMed ID: 17620960
[TBL] [Abstract][Full Text] [Related]
37. Reduced P-selectin in hearts pretreated with fluvastatin: a novel benefit for patients undergoing open heart surgery.
Berkan O; Katrancioglu N; Ozker E; Ozerdem G; Bakici Z; Yilmaz MB
Thorac Cardiovasc Surg; 2009 Mar; 57(2):91-5. PubMed ID: 19241310
[TBL] [Abstract][Full Text] [Related]
38. Role of RAS inhibition in the regulation of Cu/Zn-SOD in the cardiac and peripheral arterial beds in humans.
Kuster GM; Nietlispach F; Kiowski W; Schindler R; Bernheim A; Schuetz P; Mueller B; Morgenthaler NG; Rüter F; Riesen W; Rickli H; Brunner-La Rocca HP
Clin Pharmacol Ther; 2010 Jun; 87(6):686-92. PubMed ID: 20445533
[TBL] [Abstract][Full Text] [Related]
39. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
Hermida RC; Ayala DE; Fontao MJ; Mojón A; Fernández JR
Chronobiol Int; 2010 Jul; 27(6):1287-303. PubMed ID: 20653455
[TBL] [Abstract][Full Text] [Related]
40. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
